Clinical Trials

Tricida announces closing of $57.5m series D financing

Tricida has closed an oversubscribed $57.5m series D financing, bringing the company’s total capital raised to-date to $153.3m.

Boehringer says Cyltezo and Humira have similar efficacy, safety in people with RA

Boehringer Ingelheim has revealed one-year data from VOLTAIRE-RA, a pivotal phase 3 clinical trial evaluating Cyltezo (adalimumab-adbm) with reference product Humira.

Trial finds blood plasma infusions could help treat Alzheimer’s

A team of researchers in the US have found that regular infusions of blood plasma from young donors could well be a new treatment option for Alzheimer’s disease.

Sanofi, Alnylam present positive complete results of patisiran from phase 3 study in hATTR amyloidosis patients with polyneuropathy

Sanofi Genzyme, and Alnylam Pharmaceuticals have reported positive complete results from the Apollo Phase 3 study of patisiran, an investigational RNAi therapeutic being developed for patients with hereditary ATTR (hATTR) amyloidosis with polyneuropathy.

AbbVie says Elagolix reduces pelvic pain in two phase 3 extension studies

AbbVie said that its gonadotropin-releasing hormone (GnRH) antagonist elagolix demonstrated sustained reduction in average monthly menstrual pelvic pain, non-menstrual pelvic pain and painful intercourse in two replicate Phase 3 extension studies.

AbbVie’s psoriasis drug meets co-primary endpoints in three phase 3 trials

AbbVie’s psoriasis drug risankizumab has met all co-primary and ranked secondary points in three pivotal phase 3 clinical trials.

Novartis pediatric multiple sclerosis drug Gilenya shows significant effect in phase III trial

Novartis has announced full results from the phase III PARADIGMS study, investigating the safety and efficacy of Gilenya (fingolimod) versus interferon beta-1a, in children and adolescents (ages 10 to 17) with multiple sclerosis (MS).

Study uses genomics to make treatment recommendations for recurrent glioblastoma patients

A study led by the Translational Genomics Research Institute (TGen), UC San Francisco (UCSF) and the Ivy Foundation Early Phase Clinical Trials Consortium has used genomics to make treatment recommendations for recurrent glioblastoma patients.

Gilead Sciences’ GS-0976 shows positive effect in phase 2 NASH study

Gilead Sciences announced results from a Phase 2, randomized, placebo-controlled trial evaluating two doses of GS-0976, an oral, investigational inhibitor of Acetyl-CoA carboxylase (ACC), in patients with nonalcoholic steatohepatitis (NASH).